Den europeiske union - norsk - EMA (European Medicines Agency)

linde healthcare ab - nitrogenoksid - hypertension, pulmonary; respiratory insufficiency - andre åndedrettsprodukter - inomax, i forbindelse med ventilatory støtte og andre aktuelle aktive stoffene, er angitt:for behandling av nyfødte spedbarn ≥34 svangerskapsuke med hypoksisk respiratorisk svikt forbundet med kliniske eller echocardiographic bevis for pulmonal hypertensjon, for å bedre oksygenering og for å redusere behovet for ekstrakorporal membrane oxygenation;som en del av behandling av peri - og postoperative pulmonal hypertensjon hos voksne og nyfødte barn, spedbarn og småbarn, barn og ungdom i alderen 0-17 år i forbindelse hjerte-kirurgi, for å selektivt senke pulmonal arteriell press og forbedre høyre ventrikkel-funksjon og oksygenering.

Norge - norsk - Statens legemiddelverk

air liquide santé international - nitrogenmonoksid - medisinsk gass, komprimert - 800 ppm (mol pr. mol)

Den europeiske union - norsk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibrose - andre åndedrettsprodukter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Den europeiske union - norsk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - orkambi tabletter er angitt for behandling av cystisk fibrose (cf) hos pasienter i alderen 6 år og eldre som er homozygote for f508del-mutasjon i cftr-genet. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Den europeiske union - norsk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Den europeiske union - norsk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystisk fibrose - andre åndedrettsprodukter - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Norge - norsk - Statens legemiddelverk

ratiopharm gmbh - venlafaksinhydroklorid - depotkapsel, hard - 37.5 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - venlafaksinhydroklorid - depotkapsel, hard - 75 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - venlafaksinhydroklorid - depotkapsel, hard - 150 mg

Norge - norsk - Statens legemiddelverk

krka sverige ab - venlafaksinhydroklorid - depotkapsel, hard - 150 mg